Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study.

Mobarrez F, Egberg N, Antovic J, Bröijersen A, Jörneskog G, Wallén H.

Thromb Res. 2012 Jan;129(1):95-7. doi: 10.1016/j.thromres.2011.09.027. Epub 2011 Oct 27. No abstract available.

PMID:
22035651
2.

Impaired red blood cell deformability in patients with coronary artery disease and diabetes mellitus.

Keymel S, Heiss C, Kleinbongard P, Kelm M, Lauer T.

Horm Metab Res. 2011 Oct;43(11):760-5. doi: 10.1055/s-0031-1286325. Epub 2011 Oct 18.

PMID:
22009370
3.

Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population.

Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H; RISC Investigators.

J Intern Med. 2012 Mar;271(3):294-304. doi: 10.1111/j.1365-2796.2011.02442.x. Epub 2011 Sep 14.

4.

Involvement of microparticles in diabetic vascular complications.

Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A.

Thromb Haemost. 2011 Aug;106(2):310-21. doi: 10.1160/TH10-11-0712. Epub 2011 Jun 28.

PMID:
21713319
5.

Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms.

Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M, Anselmo RM, Marchant K, Barnard J, Silverstein RL.

Blood. 2011 Jun 9;117(23):6355-66. doi: 10.1182/blood-2011-02-338582. Epub 2011 Apr 8.

6.

Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles.

Jung KH, Chu K, Lee ST, Bahn JJ, Kim JH, Kim M, Lee SK, Roh JK.

Cerebrovasc Dis. 2011;31(5):485-93. doi: 10.1159/000324383. Epub 2011 Mar 16.

PMID:
21411989
7.

The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles.

Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF.

J Thromb Haemost. 2011 Apr;9(4):844-51. doi: 10.1111/j.1538-7836.2011.04220.x.

8.

The plasma microparticle proteome.

Little KM, Smalley DM, Harthun NL, Ley K.

Semin Thromb Hemost. 2010 Nov;36(8):845-56. doi: 10.1055/s-0030-1267038. Epub 2010 Nov 3.

PMID:
21049385
9.

Microparticles: protagonists of a novel communication network for intercellular information exchange.

Mause SF, Weber C.

Circ Res. 2010 Oct 29;107(9):1047-57. doi: 10.1161/CIRCRESAHA.110.226456. Review.

10.

Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.

Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S, Connelly MA, Abumrad NA.

Hum Mol Genet. 2011 Jan 1;20(1):193-201. doi: 10.1093/hmg/ddq449. Epub 2010 Oct 8.

11.

Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.

Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B.

Clin Chim Acta. 2010 Dec 14;411(23-24):2079-82. doi: 10.1016/j.cca.2010.09.009. Epub 2010 Sep 16.

PMID:
20837002
12.

Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop.

Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F; ISTH SSC Workshop.

J Thromb Haemost. 2010 Nov;8(11):2571-4. doi: 10.1111/j.1538-7836.2010.04047.x. No abstract available.

13.

Circulating endothelial microparticles in diabetes mellitus.

Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L.

Mediators Inflamm. 2010;2010:250476. doi: 10.1155/2010/250476. Epub 2010 Jun 16.

14.

Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress.

Helal O, Defoort C, Robert S, Marin C, Lesavre N, Lopez-Miranda J, Risérus U, Basu S, Lovegrove J, McMonagle J, Roche HM, Dignat-George F, Lairon D.

Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):665-71. doi: 10.1016/j.numecd.2010.01.004. Epub 2010 Apr 15.

PMID:
20399083
15.

Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk.

Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW.

J Clin Endocrinol Metab. 2010 Apr;95(4):1939-46. doi: 10.1210/jc.2009-2002. Epub 2010 Feb 5.

PMID:
20139232
16.

Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.

Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S.

J Atheroscler Thromb. 2010 Jun 30;17(6):539-45. Epub 2010 Feb 5.

17.

Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied.

van Ierssel SH, Van Craenenbroeck EM, Conraads VM, Van Tendeloo VF, Vrints CJ, Jorens PG, Hoymans VY.

Thromb Res. 2010 Apr;125(4):332-9. doi: 10.1016/j.thromres.2009.12.019. Epub 2010 Feb 1.

PMID:
20117824
18.

Comparative proteomics of erythrocyte aging in vivo and in vitro.

Bosman GJ, Lasonder E, Groenen-Döpp YA, Willekens FL, Werre JM, Novotný VM.

J Proteomics. 2010 Jan 3;73(3):396-402. doi: 10.1016/j.jprot.2009.07.010. Epub 2009 Aug 4. Review.

PMID:
19660581
19.

Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36.

Silverstein RL.

Cleve Clin J Med. 2009 Apr;76 Suppl 2:S27-30. doi: 10.3949/ccjm.76.s2.06. Review.

20.

Cell-derived microparticles in haemostasis and vascular medicine.

Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A.

Thromb Haemost. 2009 Mar;101(3):439-51. Review.

PMID:
19277403

Supplemental Content

Support Center